Endometrial Cancer - Pipeline Review, H1 2016

Description: Endometrial Cancer - Pipeline Review, H1 2016

Summary

‘Endometrial Cancer - Pipeline Review, H1 2016’, provides an overview of the Endometrial Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
- The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects
- The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Endometrial Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Endometrial Cancer Overview
Therapeutics Development
Pipeline Products for Endometrial Cancer - Overview
Pipeline Products for Endometrial Cancer - Comparative Analysis
Endometrial Cancer - Therapeutics under Development by Companies
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes
Endometrial Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Endometrial Cancer - Products under Development by Companies
Endometrial Cancer - Products under Investigation by Universities/Institutes
Endometrial Cancer - Companies Involved in Therapeutics Development
Ability Pharmaceuticals, S.L.
Advence Therapeutics, LLC
Aeterna Zentaris Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
BeiGene, Ltd.
BioNTech AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cellceutix Corporation
Critical Outcome Technologies Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Esperance Pharmaceuticals, Inc.
Exelisis, Inc.
Galena Biopharma, Inc.
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc.
Horizon Pharma Plc
ImmunoGen, Inc.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
OncoHoldings, Inc.
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Pharma Mar, S.A.
Pharmsynthez
Pivot Pharmaceuticals Inc
Puma Biotechnology, Inc.
Sanofi
Shenogen Pharma Group Ltd.
Synthon Holdings BV
Vertex Pharmaceuticals Incorporated
Vyriad
Endometrial Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
²¹²Pb-TCMC-Trastuzumab - Drug Profile
ABTL-0812 - Drug Profile
AEZS-125 - Drug Profile
AL-3818 - Drug Profile
ARQ-092 - Drug Profile
AV-203 - Drug Profile
AZD-2014 - Drug Profile
AZD-5363 - Drug Profile
BGB-283 - Drug Profile
buparlisib hydrochloride - Drug Profile
cabozantinib s-malate - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Ovarian and Endometrial Cancer - Drug Profile
Cellular Immunotherapy to Taregt HER-2 for Oncology - Drug Profile
COTI-2 - Drug Profile
cridanimod - Drug Profile
DT-1154 - Drug Profile
EP-200 - Drug Profile
epacadostat - Drug Profile
everolimus - Drug Profile
GALE-301 - Drug Profile
gemogenovatucel-T - Drug Profile
GSK-2636771 - Drug Profile
HO-3867 - Drug Profile
INCB-50465 - Drug Profile
INCB-54828 - Drug Profile
interferon gamma-1b - Drug Profile
itacitinib adipate - Drug Profile
KM-3174 - Drug Profile
levalatanib mesylate - Drug Profile
lurbinectedin - Drug Profile
LY-3023414 - Drug Profile
mirvetuximab soravtansine - Drug Profile
MK-2206 - Drug Profile
Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile
neratinib - Drug Profile
nintedanib - Drug Profile
onapristone ER - Drug Profile
ONCO-101 - Drug Profile
Oncolytic Virus to Activate IFNb for Endometrial Cancer - Drug Profile
Oncolytic Virus to Target CD46 for Gynecological Cancers and Urinary Tract Cancer - Drug Profile
OPB-111001 - Drug Profile
Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile
PF-06671008 - Drug Profile
pimasertib hydrochloride + voxtalisib - Drug Profile
PVT-005 - Drug Profile
sapanisertib - Drug Profile
SAR-408701 - Drug Profile
selinexor - Drug Profile
sirolimus albumin-bound - Drug Profile
Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma - Drug Profile
SNG-1153 - Drug Profile
SP-2509 - Drug Profile
SYD-985 - Drug Profile
talazoparib - Drug Profile
Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

Endometrial Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016
Endometrial Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016
Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016
Endometrial Cancer - Pipeline by ArQule, Inc., H1 2016
Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2016
Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
Endometrial Cancer - Pipeline by BeiGene, Ltd., H1 2016
Endometrial Cancer - Pipeline by BioNTech AG, H1 2016
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
Endometrial Cancer - Pipeline by Cellceutix Corporation, H1 2016
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2016
Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2016
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2016
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2016
Endometrial Cancer - Pipeline by Genmab A/S, H1 2016
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
Endometrial Cancer - Pipeline by Gradalis Inc., H1 2016
Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2016
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2016
Endometrial Cancer - Pipeline by Incyte Corporation, H1 2016
Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Endometrial Cancer - Pipeline by Medivation, Inc., H1 2016
Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2016
Endometrial Cancer - Pipeline by Merck KGaA, H1 2016
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Endometrial Cancer - Pipeline by Novartis AG, H1 2016
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2016
Endometrial Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
Endometrial Cancer - Pipeline by Pfizer Inc., H1 2016
Endometrial Cancer - Pipeline by Pharma Mar, S.A., H1 2016
Endometrial Cancer - Pipeline by Pharmsynthez, H1 2016
Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2016
Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016
Endometrial Cancer - Pipeline by Sanofi, H1 2016
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016
Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2016
Endometrial Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
Endometrial Cancer - Pipeline by Vyriad, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2016
Endometrial Cancer - Dormant Projects, H1 2016
Endometrial Cancer - Dormant Projects (Contd..1), H1 2016
Endometrial Cancer - Dormant Projects (Contd..2), H1 2016
Endometrial Cancer - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Endometrial Cancer, H1 2016
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3753855/](http://www.researchandmarkets.com/reports/3753855/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Endometrial Cancer - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3753855/
Office Code: SCH3XYGR

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World